This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck's Gardasil Gets FDA Approval for Head and Neck Cancers
by Zacks Equity Research
FDA grants accelerated approval for label expansion application of Merck's (MRK) human papillomavirus vaccine, Gardasil, to include oropharyngeal and other head and neck cancers.
Dr. Reddy's Inks Deal With Gilead Sciences for Remdesivir
by Zacks Equity Research
Dr. Reddy Laboratories (RDY) inks a deal with Gilead to register, manufacture and sell the latter's Remdesivir ??? a potential treatment for COVID-19 ??? in 127 countries including India.
AstraZeneca to Supply 400M Coronavirus Vaccine Doses in Europe
by Zacks Equity Research
AstraZeneca's (AZN) supply deals will require it to produce 2 billion doses of the vaccine, if it is successfully developed.
Top Research Reports for Johnson & Johnson, Walmart & Bank of America
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Walmart (WMT) and Bank of America (BAC).
Moderna a Step Closer to Coronavirus Vaccine: ETFs to Gain
by Sweta Jaiswal, FRM
Moderna informs that the final-stage trial's primary aim will be to prevent the spread of coronavirus.
Emergent (EBS) to Manufacture AstraZeneca's Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions (EBS) inks a deal with AstraZeneca to provide its CDMO services for supporting the manufacturing of the latter's COVID-19 vaccine candidate, AZD1222.
Novo Nordisk to Acquire Corvidia Therapeutics for $725M Cash
by Zacks Equity Research
Novo Nordisk (NVO) enters into a deal to acquire Corvidia Therapeutics for an upfront payment of $725 million in cash.
Bristol-Myers Gets FDA Nod for Label Expansion of Opdivo
by Zacks Equity Research
Bristol-Myers (BMY) gets FDA nod for Opdivo for the treatment of esophageal squamous cell carcinoma.
AbbVie Inks Deal With Genmab, Announces ADC Candidate Data
by Zacks Equity Research
AbbVie (ABBV) signs deal with Genmab to jointly develop three early-stage bispecific antibody product candidates. Its novel ADC candidate, ABBV-3373 demonstrates clinical activity in study.
RedHill Files CTA for Coronavirus Study on Opaganib in Russia
by Zacks Equity Research
RedHill (RDHL) submits a Clinical Trial Application in Russia for a phase II/III study on opaganib to treat patients detected with severe COVID-19 infection and pneumonia. Stock up.
Karyopharm Starts Dosing in Selinexor Study for Glioblastoma
by Zacks Equity Research
Karyopharm (KPTI) commences a phase I/II study evaluating Xpovio (selinexor) in combination with standard-of-care therapy in patients with newly-diagnosed or recurrent glioblastoma.
Lilly Begins Cardiovascular Outcomes Study on Tirzepatide
by Zacks Equity Research
Lilly (LLY) announces that the first patient dose has been delivered in a cardiovascular outcome study on its novel diabetes candidate, tirzepatide.
Gilead Up on Report of AstraZeneca's Interest in Merger
by Zacks Equity Research
Gilead (GILD) gains after report surfaces that AstraZeneca has shown interest in the former last month.
FibroGen Initiates Phase II/III Study in Severe Coronavirus
by Zacks Equity Research
FibroGen (FGEN) starts a phase II/III study in Italy on pamrevlumab versus standard of care in patients with severe COVID-19 infection.
Company News for Jun 9, 2020
by Zacks Equity Research
Companies In The News Are: THO, ROKU, GILD, AZN, TSLA.
Merck's Antibiotic Recarbrio Gets FDA Nod for New Indication
by Zacks Equity Research
The FDA approves Merck's (MRK) sNDA seeking approval for its antibacterial injection Recarbrio regarding a new indication. The application was filed in February 2020.
AstraZeneca's Calquence Shows Promise as Coronavirus Treatment
by Zacks Equity Research
Peer-reviewed data on AstraZeneca's (AZN) Calquence shows that it improves laboratory markers of inflammation and decreases oxygen requirements in most patients hospitalized due to COVID-19.
AstraZeneca Reportedly Approaches Gilead for Potential Merger
by Zacks Equity Research
If AstraZeneca (AZN) and Gilead (GILD) were to combine into one, it would be the biggest health-care deal ever.
Novavax Clinches $60M Defense Contract for Coronavirus Vaccine
by Zacks Equity Research
Novavax (NVAX) secures a $60-million pact from the US Department of Defense to manufacture its COVID-19 vaccine candidate, NVX-CoV2373.
AstraZeneca to Ensure Equal Access to Coronavirus Vaccine
by Zacks Equity Research
AstraZeneca (AZN) signs three new supply deals to ensure broad and equitable global access to its COVID-19 vaccine following its successful development.
Pharma Stock Roundup: LLY Coronavirus Antibody Phase I Study Initiation, FDA Approvals
by Kinjel Shah
Lilly (LLY) begins phase I study on a potential COVID-19 antibody therapy. FDA grants label expansion approvals to several drugs.
Trump Picks 5 Coronavirus Vaccine Candidates Per NYT Report
by Kinjel Shah
The candidates belong to five companies, Moderna, AstraZeneca, J&J, Merck and Pfizer.
AstraZeneca Inks Deal to Develop RMP Inhibitors for Cancer
by Zacks Equity Research
AstraZeneca (AZN) signs an oncology agreement with Accent Therapeutics to develop novel therapies targeting RNA-modifying proteins for treating cancer.
FDA Okays AVEO's NDA Filing for Treating Renal Cell Carcinoma
by Zacks Equity Research
AVEO's new drug application submission for tivozanib as a treatment of relapsed or refractory renal cell carcinoma gets acceptance from the FDA. A decision is expected on Mar 31, 2021.
Top Ranked Income Stocks to Buy for June 2nd
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, June 2nd.